Cover Image
市場調查報告書

全球癲癇治療藥市場

Global Epilepsy Market 2014-2018

出版商 TechNavio (Infiniti Research Ltd.) 商品編碼 232641
出版日期 內容資訊 英文 78 Pages
訂單完成後即時交付
價格
Back to Top
全球癲癇治療藥市場 Global Epilepsy Market 2014-2018
出版日期: 2014年11月05日 內容資訊: 英文 78 Pages
簡介

全球癲癇治療藥市場,預計從2013年到2018年之間,以5.06%的年複合成長率擴大。

本報告提供全球癲癇治療藥市場現狀與今後的預測、各地區的趨勢、市場成長要素與課題、主要企業簡介等資訊。

第1章 摘要整理

第2章 簡稱清單

第3章 調查範圍

  • 市場概要
  • 主要的產品

第4章 市場調查手法

  • 市場調查流程
  • 調查手法

第5章 簡介

第6章 市場形勢

  • 市場概要
  • 市場規模與預測
  • 波特的五力分析

第7章 各藥物世代的市場區隔

第8章 地理區隔

  • 南北美洲
  • 歐洲、中東、非洲地區
  • 亞太地區

第9章 購買標準

第10章 市場成長因素

第11章 成長因素與其影響

第12章 市場課題

第13章 成長因素與課題的影響

第14章 市場趨勢

第15章 趨勢與其影響

第16章 業者情勢

  • 競爭模式
    • 主要消息
    • M&A
  • 市場佔有率分析
    • Pfizer
    • UCB
    • GlaxoSmithKline
  • 其他卓越供應商

第17章 主要供應商分析

  • GlaxoSmithKline
  • Pfizer
  • UCB

第18章 相關報告

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: IRTNTR4492

About Epilepsy

Epilepsy is defined as a spectrum of brain disorders varying from benign symptoms to severe, disabling, and life-threatening symptoms. It can be caused by various factors ranging from brain malformations and tumors to meningitis, high-risk pregnancies, and birth trauma. However, when the underlying cause of the disease is unidentified, as occurs in majority of the cases, it is known as idiopathic epilepsy. Epilepsy is characterized by repeated occurrence of generalized or focal seizures. Seizures result from an imbalance between the inhibitory and excitatory signals of the brain leading to sudden-onset of excitation. The occurrence of two or more unprovoked seizures is an important criteria to diagnose a person with seizures as being epileptic.

TechNavio's analysts forecast the Global Epilepsy market to grow at a CAGR of 5.06 percent over the period 2013-2018.

Covered in this Report

This report covers the present scenario and the growth prospects of the Global Epilepsy market for the period 2014-2018. To calculate the market size, the report considers revenue generated through the sales of anti-epileptic drugs approved for the treatment of symptoms of epilepsy.

TechNavio's report, Global Epilepsy Market 2014-2018, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, and the EMEA and APAC regions; it also covers the Global Epilepsy market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.

Key Regions

  • Americas
  • APAC
  • EMEA

Key Vendors

  • GlaxoSmithKline
  • Pfizer
  • UCB

Other Prominent Vendors

  • Abbvie
  • Eisai
  • F. Hoffmann-La Roche
  • H. Lundbeck
  • Janssen Pharmaceuticals
  • Meda AB
  • Novartis
  • Shire
  • Sunovion Pharmaceuticals
  • Supernus Pharmaceuticals
  • Upsher-Smith Laboratories
  • Valeant Pharmaceuticals International

Market Driver

  • Unmet Medical Needs
  • For a full, detailed list, view our report

Market Challenge

  • Generic Erosion
  • For a full, detailed list, view our report

Market Trend

  • Reformulation of Marketed Drugs
  • For a full, detailed list, view our report

Key Questions Answered in this Report

  • What will the market size be in 2018 and what will the growth rate be
  • What are the key market trends
  • What is driving this market
  • What are the challenges to market growth
  • Who are the key vendors in this market space
  • What are the market opportunities and threats faced by the key vendors
  • What are the strengths and weaknesses of the key vendors

Table of Contents

01. Executive Summary

02. List of Abbreviations

03. Scope of the Report

  • 03.1. Market Overview
  • 03.2. Product Offerings

04. Market Research Methodology

  • 04.1. Market Research Process
  • 04.2. Research Methodology

05. Introduction

06. Market Landscape

  • 06.1. Market Overview
  • 06.2. Market Size and Forecast
  • 06.3. Five Forces Analysis

07. Market Segmentation by Generation of Drugs

08. Geographical Segmentation

  • 08.1. Epilepsy Market in the Americas
    • 08.1.1. Market Size and Forecast
  • 08.2. Epilepsy Market in the EMEA Region
    • 08.2.1. Market Size and Forecast
  • 08.3. Epilepsy Market in the APAC Region
    • 08.3.1. Market Size and Forecast

09. Buying Criteria

10. Market Growth Drivers

11. Drivers and their Impact

12. Market Challenges

13. Impact of Drivers and Challenges

14. Market Trends

15. Trends and their Impact

16. Vendor Landscape

  • 16.1. Competitive Scenario
    • 16.1.1. Key News
    • 16.1.2. Mergers and Acquisitions
  • 16.2. Market Share Analysis 2013
    • 16.2.1. Pfizer
    • 16.2.2. UCB
    • 16.2.3. GlaxoSmithKline
  • 16.3. Other Prominent Vendors

17. Key Vendor Analysis

  • 17.1. GlaxoSmithKline
    • 17.1.1. Key Facts
    • 17.1.2. Business Overview
    • 17.1.3. Business Segmentation
    • 17.1.4. Business Segmentation by Revenue 2012 and 2013
    • 17.1.5. Sales by Geography
    • 17.1.6. Pipeline Products
    • 17.1.7. Business Strategy
    • 17.1.8. Key Information
    • 17.1.9. SWOT Analysis
  • 17.2. Pfizer
    • 17.2.1. Key Facts
    • 17.2.2. Business Overview
    • 17.2.3. Business Segmentation by Revenue 2013
    • 17.2.4. Business Segmentation by Revenue 2012 and 2013
    • 17.2.5. Geographical Segmentation by Revenue
    • 17.2.6. Business Strategy
    • 17.2.7. Key Developments
    • 17.2.8. SWOT Analysis
  • 17.3. UCB

18. Other Reports in this Series

List of Exhibits

  • Exhibit 1: Market Research Methodology
  • Exhibit 2: Global Epilepsy Market 2013-2018 (US$ million)
  • Exhibit 3: Global Epilepsy Market Segmentation by Generation of Drugs
  • Exhibit 4: Revenue and CAGR of Major Epilepsy Markets 2013 (US$ million)
  • Exhibit 5: Global Epilepsy Market by Geographical Segmentation 2013
  • Exhibit 6: Global Epilepsy Market by Geographical Segmentation 2018
  • Exhibit 7: Global Epilepsy Market by Geographical Segmentation 2013-2018 (US$ million)
  • Exhibit 8: Global Epilepsy Market by Geographical Segmentation 2013-2018
  • Exhibit 9: Epilepsy Market in the Americas 2013-2018
  • Exhibit 10: Epilepsy Market in the Americas by Geography 2013 (US$ million)
  • Exhibit 11: Epilepsy Market in North America 2013-2018
  • Exhibit 12: Epilepsy Market in the US 2013-2018
  • Exhibit 13: Epilepsy Market in Canada 2013-2018
  • Exhibit 14: Epilepsy Market in EMEA by Geography 2013
  • Exhibit 15: Epilepsy Market in EMEA 2013-2018
  • Exhibit 16: Epilepsy Market in Europe 2013-2018
  • Exhibit 17: Epilepsy Market in APAC by Geography 2013
  • Exhibit 18: Revenue and CAGR of Epilepsy Market in APAC by Geography 2013 (US$ million)
  • Exhibit 19: Epilepsy Market in APAC 2013-2018
  • Exhibit 20: Epilepsy Market in Japan 2013-2018
  • Exhibit 21: Epilepsy Market in Australia 2013-2018
  • Exhibit 22: Epilepsy Market in China 2013-2018
  • Exhibit 23: Epilepsy Market in India 2013-2018
  • Exhibit 24: Impact of loss of exclusivity in Canadian market for Lyrica
  • Exhibit 25: Lyrica Revenue 2011-2013 (US$ million)
  • Exhibit 26: Neurontin Revenue 2011-2013 (US$ million)
  • Exhibit 27: Vimpat Revenue 2011-2013 (US$ million)
  • Exhibit 28: Vimpat Sales by Geographical Segmentation 2013
  • Exhibit 29: Keppra/Keppra XR Revenue 2011-2013 (US$ million)
  • Exhibit 30: Keppra/Keppra XR Sales by Geographical Segmentation 2013
  • Exhibit 31: Lamictal Revenue 2011-2013 (US$ million)
  • Exhibit 32: Lamictal Sales by Geographical Segmentation 2013
  • Exhibit 33: GlaxoSmithKline: Business Segmentation 2013
  • Exhibit 34: GlaxoSmithKline: Business Segmentation by Revenue 2012 and 2013 (US$ billion)
  • Exhibit 35: GlaxoSmithKline: Sales by Geography 2013
  • Exhibit 36: GlaxoSmithKline: Pipeline Products 2013
  • Exhibit 37: Pfizer: Business Segmentation by Revenue 2013
  • Exhibit 38: Pfizer: Business Segmentation by Revenue 2012 and 2013
  • Exhibit 39: Pfizer: Geographical Segmentation by Revenue 2013
Back to Top